These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33813727)

  • 21. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
    Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
    Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.
    Lam ASM; Yan BPY; Lee VWY
    Clin Cardiol; 2021 Aug; 44(8):1072-1079. PubMed ID: 34041774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
    Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry.
    Kang J; Han JK; Yang HM; Park KW; Kang HJ; Koo BK; Choo EH; Lee JY; Park SD; Lim YH; Kim HM; Heo JH; Kim HS
    BMC Cardiovasc Disord; 2023 Jan; 23(1):6. PubMed ID: 36624388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
    Alexopoulos D; Xanthopoulou I; Deftereos S; Hamilos M; Sitafidis G; Kanakakis I; Pentara I; Vavouranakis M; Davlouros P; Hahalis G; Goudevenos J
    J Thromb Haemost; 2016 Jun; 14(6):1146-54. PubMed ID: 26990959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
    Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study.
    Soueid AE; Kassas I; Rade J; Kakouros N
    J Invasive Cardiol; 2021 Apr; 33(4):E263-E268. PubMed ID: 33794478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of prasugrel for the secondary prevention of atherothrombosis.
    Spinler SA; Rees C
    J Manag Care Pharm; 2009 Jun; 15(5):383-95. PubMed ID: 19496635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial).
    Jin C; Kim MH; Guo LZ; Jin E; Shin ES; Ann SH; Cho YR; Park JS; Kim SJ; Lee MS
    Int J Cardiol; 2020 Apr; 305():11-17. PubMed ID: 32029306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
    Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL
    Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
    Alexopoulos D; Xanthopoulou I; Plakomyti TE; Theodoropoulos KC; Mavronasiou E; Damelou A; Hahalis G; Davlouros P
    Am Heart J; 2013 Jan; 165(1):73-9. PubMed ID: 23237136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
    JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.